1 |
National Comprehensive Cancer Network. Clinical Practice Guideline in OncologyTM, Colon cancer Version 3 (2020). Available from http://www.nccn.org. Accessed July 20, 2020.
|
2 |
National Comprehensive Cancer Network. Clinical Practice Guideline in OncologyTM, Rectal cancer Version 3 (2020). Available from http://www.nccn.org Accessed July 20, 2020.
|
3 |
Korea Central Cancer Registy, National Cancer Center: Annual report of cancer statistics in Korea 2017. Available from http://www.ncc.re.kr. Accessed July 20, 2020.
|
4 |
National Cancer Information Center: Colorectal cancer. Available from http://www.cancer.go.kr. Accessed July 20, 2020.
|
5 |
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42.
DOI
|
6 |
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-9.
DOI
|
7 |
Van Cutsem E, Kohne CH, Hitreet E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17.
DOI
|
8 |
Bennouna J, Sastre J, Arnold J, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37.
DOI
|
9 |
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065-75.
DOI
|
10 |
Micromedex solutions. IBM Watson Health, Greenwood Village, CO. Available from https://www.micromedexsolutions.com. Accessed July 20, 2020.
|
11 |
Tanaka H, Takahashi K, Yamaguchi K, et al. Hypertension and proteinuria as predictive factors of effects of bevacizumab on advanced breast cancer in Japan. Biol Pharm Bull 2018;41(4):644-8.
DOI
|
12 |
Feliu J, Salud A, Safont MJ, et al. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 2015;10(1):e0116527.
DOI
|
13 |
Jane A, Joseph F, Roaa AG, et al. Drug information handbook 28th ed. North American: Wolters Kluwer, 2019; 281-5.
|
14 |
Heo H, Choi JS, Im HJ, et al. Hypertension and clinical outcome in metastatic colorectal cancer patients treated with bevacizumab. J. Kor. Soc. Health-Syst. Pharm 2012;29(3):324-37.
DOI
|
15 |
Yan LZ, Dressler EV, Adams VR. Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens. J Oncol Pharm Pract 2018;24(3):209-17.
DOI
|
16 |
Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget 2017;8(31):51492-506.
DOI
|
17 |
Iwasa S, Nakajima TE, Nagashima K, et al. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res 2013;33(1):309-16.
|
18 |
Uysal M, Bozcuk H, Göksu SS, et al. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother 2014;68(4):409-12.
DOI
|
19 |
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134(5):1296-310.
DOI
|
20 |
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506.
DOI
|
21 |
Kim H. Differential diagnosis and treatment of proteinuria. Korean J Med 2013;85(4):374-7.
DOI
|
22 |
Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21(8):1381-9.
DOI
|
23 |
Lafayette R, McCall B, Li N, et al. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am J Nephrol 2014;40(1):75-83.
DOI
|